Author

U. Banerji

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. A. Antolin· 1 shared A. Acar· 1 shared A. Sottoriva· 1 shared A. Stewart· 1 shared B. Al-Lazikani· 1 shared C. C. Maley· 1 shared D. Nichol· 1 shared G. D. Cresswell· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. A. Antolin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 4, 2019

Exploiting evolutionary herding to control drug resistance in cancer

A. Acar, D. Nichol, J. Fernandez…·A. Sottoriva

This paper demonstrates evolutionary herding in non-small cell lung cancer to control drug resistance by shifting clonal composition and inducing collateral sensitivity.

DOI 10.1101/566950

humanscRNA-seq

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivJan 14, 2019

The off-target kinase landscape of clinical PARP inhibitors

A. A. Antolin, M. Ameratunga, U. Banerji…·B. Al-Lazikani

This study identifies the off-target kinase profiles of four FDA-approved PARP inhibitors, revealing unique polypharmacological effects with potential clinical implications.

DOI 10.1038/s41598-020-59074-4

experimental assaydrug response / drug discovery

𝕏 PostBluesky